Skip to main content
Search
News, Views, and Advocacy From the Oncology Nursing Society
ONS Voice Home
  • News & Views
  • Advocacy
  • Stories
  • Instagram
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • RSS
  • News & Views
    • Latest Articles
    • Clinical Practice
    • ONS News
    • ONS Leadership
    Trending Topics
    • Research
    • Treatments
    • Safety
    • COVID-19
    • Drug Reference Sheet
    • Special Populations
    View All Topics
    Advocacy
    • Latest Articles
    • Updates
    • Get Involved
    Stories View All
    View All
    Innovative Oncology Nurses Break Down Communication Barriers for Patients Who Are Deaf or Hard of Hearing
    Special Populations
    Innovative Oncology Nurses Break Down Communication Barriers for Patients Who Are Deaf or Hard of Hearing
    March 10, 2023
    How I Practice Mindfulness as an Oncology Nurse
    Nurse well-being
    How I Practice Mindfulness as an Oncology Nurse
    March 03, 2023
    Clinical and Pharmaceutical Nurse Educators Collaborate to Bring Training to Nurses and Improve Patient Care
    Oncology nurse education
    Clinical and Pharmaceutical Nurse Educators Collaborate to Bring Training to Nurses and Improve Patient Care
    January 13, 2023
    Oncology Nurse Uses Retirement to Help Patients and Healthcare Professionals Understand Pancreatic Cancer Biomarker Testing Results
    Pancreatic cancer
    Oncology Nurse Uses Retirement to Help Patients and Healthcare Professionals Understand Pancreatic Cancer Biomarker Testing Results
    November 11, 2022
    The Life of Marie Curie and Her Contributions to Oncology
    Cancer treatments
    The Life of Marie Curie and Her Contributions to Oncology
    November 07, 2022
    previous slide
    next slide
    Search
  • News & Views
  • Advocacy
  • Stories
  • Topic

    Treatments

    Platinum Chemo Improves TNBC Survival for Patients Younger Than 50
    Chemotherapy

    Platinum Chemo Improves TNBC Survival for Patients Younger Than 50

    Adding carboplatin to standard neoadjuvant chemotherapy for patients with triple-negative breast cancer improves complete response, event-free survival, and overall survival, researchers reported in study findings presented in abstract GS5-01 during the 2022 San Antonio Breast Cancer Symposium. 

    March 29, 2023
    Annual Report to the Nation Says Cancer Deaths Continue Downward Trend
    Cancer research

    Annual Report to the Nation Says Cancer Deaths Continue Downward Trend

    Overall cancer death rates continued to decline from 2015–2019 among men, women, children, adolescents, and young adults in every major racial and ethnic group, according to the October 2022 Annual Report to the Nation on the Status of Cancer. The National Cancer Institute, Centers for Disease Control and Prevention, American Cancer Society, and North American Association of Central Cancer Registries jointly issue the report each year to monitor cancer trends across society.

    January 11, 2023
    Cortisol Biomarkers Help Researchers Understand Chemotherapy-Induced Peripheral Neuropathy
    Chemotherapy

    Cortisol Biomarkers Help Researchers Understand Chemotherapy-Induced Peripheral Neuropathy

    Clinicians and researchers know little about the mechanisms for chemotherapy-induced peripheral neuropathy, a side effect of neurotoxic agents that can cause numbness, tingling, and pain in the upper and lower extremities. Until recently, mechanism-based treatment was difficult, but biomarkers are helping nurse scientists identify a potential connection to the hypothalamic-pituitary-adrenal axis.

    November 03, 2022
    FDA Recommends Healthcare Providers Consider Alternatives for MRI-Guided Breast Biopsy Grid Plates Because of Shortage
    U.S. Food and Drug Administration (FDA)

    FDA Recommends Healthcare Providers Consider Alternatives for MRI-Guided Breast Biopsy Grid Plates Because of Shortage

    On October 31, 2022, the U.S. Food and Drug Administration recommended that healthcare providers discuss alternative options for magnetic resonance imaging–guided breast biopsy procedures with patients if a facility is unable to perform it because of a shortage of Philips Invivo MRI breast biopsy grid plates and other Philips Invivo MRI disposables. 

    November 02, 2022
    Androgen Receptor Signaling May Contribute to Melanoma Treatment Resistance
    Melanoma

    Androgen Receptor Signaling May Contribute to Melanoma Treatment Resistance

    Poorer outcomes among males receiving BRAF or MEK inhibitors for melanoma may be related to an increase in androgen receptors, researchers discovered in study findings published in Nature.

    October 26, 2022
    Baxter Healthcare Corporation Recalls Clearlink Basic Solution Set With Duovent Because of Leaks That Risk Exposure to Toxic Substances
    U.S. Food and Drug Administration (FDA)

    Baxter Healthcare Corporation Recalls Clearlink Basic Solution Set With Duovent Because of Leaks That Risk Exposure to Toxic Substances

    On September 15, 2022, the U.S. Food and Drug Administration reported Baxter Healthcare Corporation’s recall of Clearlink basic solution set with Duovent because of reports of leaks. FDA identified it as a class I recall, the most serious type of recall, where use of the set may cause serious injuries or death.

    September 16, 2022
    What the Evidence Says About Traditional Chinese Medicine for Chronic Diarrhea
    Research

    What the Evidence Says About Traditional Chinese Medicine for Chronic Diarrhea

    Diarrhea is a distressing condition that significantly affects patients’ quality of life and social functioning. Characterized by passage of more than three unformed stools in 24 hours, in cancer it can be caused by chemotherapy, radiotherapy, laxatives and antibiotics, enteral feeding, malabsorption syndromes, colectomy, or several types of malignant tumors. Diarrhea has also been reported in long-term cancer survivors. Standard treatment options such as opiate agonists and adsorbents are associated with side effects that may increase a patient’s symptom burden.

    July 18, 2022
    What the Evidence Says About Traditional Chinese Medicine Herbal Formula Xiao Yao San for Depression and Anxiety
    Complementary therapy

    What the Evidence Says About Traditional Chinese Medicine Herbal Formula Xiao Yao San for Depression and Anxiety

    An estimated 16% of patients with cancer experience depressive spectrum disorders in oncologic, hematologic, and palliative care settings, seriously affecting their quality of life. Although conventional antidepressants can be effective in many situations, they are associated with adverse effects, such as fatigue, drowsiness, sleep difficulties, nausea, weight gain, nervousness, dry mouth, blurred vision and sexual dysfunction.

    January 28, 2022
    Telehealth Has Value During Radiotherapy, Patients Say
    Patient resources

    Telehealth Has Value During Radiotherapy, Patients Say

    More than 90% of patients report that telehealth consultations during radiotherapy treatment are high quality and may be even better for understanding information from their healthcare team than in-person visits, researchers reported in the Journal of the National Comprehensive Cancer Network.

    December 22, 2021
    Mid-Century Antibiotic May Offer Options After PARP Inhibitor Resistance
    Cancer research

    Mid-Century Antibiotic May Offer Options After PARP Inhibitor Resistance

    Novobiocin, an antibiotic discovered during the 1950s, may be a potential second-line therapy for patients whose tumors have become resistant to poly (ADP-ribose) polymerase (PARP) inhibitors, researchers reported in Nature Cancer. The finding may open up new options for patients with BRCA-variant disease such as breast, ovarian, pancreatic, and prostate cancer.

    November 17, 2021
    Genetic Counselors Help Patients and Providers Understand Biomarker Testing Goals and Results
    Targeted therapy

    Genetic Counselors Help Patients and Providers Understand Biomarker Testing Goals and Results

    Genetic counselors have a unique ability to explain complex genetic information to patients, providers, and our healthcare colleagues and to empower patients to take an active role in their healthcare decisions. We review biosignature data points and help explain the difference between variants that were acquired (somatic) versus those that may have a germline component, or possibly inherited from a parent. By working with oncology teams, genetic counselors provide guidance on potential next steps to evaluate variation occurrences and how providers, patients, and their families can use the information to guide their care.

    November 02, 2021
    New U.S. Agency Will Propel Healthcare Advancements Directly Into Practice
    Cancer healthcare advocacy

    New U.S. Agency Will Propel Healthcare Advancements Directly Into Practice

    Biomedical research is what transforms medicine. Oncology nurses see the evidence of that daily, from discoveries like immunotherapy that have revolutionized cancer treatment to novel nursing approaches to managing symptoms and adverse events. And thanks to the studies that brought a COVID-19 coronavirus vaccine to market in record-breaking time, the world understands research like never before, too.

    October 21, 2021
    Pilot Study Shows Positive Impact of ONS Get Up, Get Moving Campaign
    Press Releases

    Pilot Study Shows Positive Impact of ONS Get Up, Get Moving Campaign

    PITTSBURGH, PA—October 12, 2021—Research shows that physical activity during cancer treatment mitigates some of the negative physical and psychosocial outcomes associated with diagnosis and treatment. Released in the October 2021 issue of the Clinical Journal of Oncology Nursing, results of a pilot study by Judi K. Forner, DNP, APRN, ACNS-BC, RN-BC, Andrea Doughty, PhD, Matthew David Dalstrom, PhD, MPH, Brandie L. Messer, DNP, RN, PCOE, and Shannon K. Lizer, PhD, APRN, FNP-BC, FAANP, demonstrated the positive impact of the Oncology Nursing Society’s (ONS’s) Get Up, Get Moving program.

    October 12, 2021
    Antibiotics May Reduce Checkpoint Inhibitor Efficacy
    Research

    Antibiotics May Reduce Checkpoint Inhibitor Efficacy

    Using antibiotics during treatment with immune checkpoint inhibitors may limit the therapy’s effect, according to study results published in the American Journal of Clinical Oncology.

    September 22, 2021
    A Body of Evidence Helps Nurses Manage CAR T-Cell Therapy Toxicities
    Cancer research

    A Body of Evidence Helps Nurses Manage CAR T-Cell Therapy Toxicities

    When chimeric antigen receptor (CAR) T-cell therapies were first approved for cancer in 2017, nurses didn’t have years of clinical practice experience with the treatment to understand its full scope of nursing implications yet. Now that nearly five years have passed—and new CAR T-cell therapies have been approved, bringing the total number of treatments to five as well—oncology nurses and nurse scientists have built a robust knowledge base.

    September 14, 2021
    ONS Bridge

    Nurses Are Key to Patients Navigating Genitourinary Cancers

    Nurses must serve as care coordinators for patients with genitourinary cancers because of the many tests, procedures, and self-care instructions they require, Clara Beaver, MSN, RN, AOCNS®, ACNS-BC®, and Joan Livingstone, BScN, RN, OCN®, both of Karmanos Cancer Institute at Wayne State University in Detroit, MI, said during a session at a ONS BridgeTM virtual conference on September 9, 2021. They emphasized the complexity of genitourinary cancers throughout diagnosis, treatment, and survivorship. Key nursing responsibilities include communicating with the care team, referring patients to other members of the interprofessional team, and advocating for patients’ needs.

    September 09, 2021
    HHS Releases New Practice Guidelines to Expand Treatment Accessibility to Americans With Opioid Use Disorder
    Clinical practice guidelines

    HHS Releases New Practice Guidelines to Expand Treatment Accessibility to Americans With Opioid Use Disorder

    Access to treatment for opioid use disorder is a priority in the Biden-Harris administration’s healthcare program, with resources from the U.S. Department of Health and Human Services (HHS) dedicated to raise awareness of the issue. In April 2021, HHS released new practice guidelines to expand evidence-based treatment to more Americans with opioid use disorder.

    August 17, 2021
    COVID-19 Reference Sheet: Vaccines
    COVID-19

    COVID-19 Reference Sheet: Vaccines

    To control the COVID-19 coronavirus pandemic, society needs public health measures (e.g., masks, physical distancing, hand washing), treatments for infection, and vaccines to prevent infection or serious disease. As the most trusted profession, nurses have a responsibility to educate patients and the community about the facts and science behind the vaccines. This reference sheet will help guide those conversations and is regularly updated as new information is released.

    December 14, 2020
    Educational Framework Offers Guidance for Oral Chemo Safety at Home
    Safety

    Educational Framework Offers Guidance for Oral Chemo Safety at Home

    One aspect that ambulatory oncology nurses must consider in the greater staffing conversation is the time spent on educating patients and caregivers about oral chemotherapy safety in the home setting. Developing an educational framework to guide those conversations not only ensures that all critical information is covered but also that it’s delivered in a standard and efficient process. 

    March 10, 2020
    FDA Approves Isatuximab-irfc for Multiple Myeloma
    U.S. Food and Drug Administration (FDA)

    FDA Approves Isatuximab-irfc for Multiple Myeloma

    On March 2, 2020, the U.S. Food and Drug Administration (FDA) approved isatuximab-irfc (Sarclisa®) in combination with pomalidomide and dexamethasone for adult patients with multiple myeloma who have received at least two prior therapies including lenalidomide and a proteasome inhibitor.

    March 02, 2020
    FDA Approves Neratinib for Metastatic HER2-Positive Breast Cancer
    U.S. Food and Drug Administration (FDA)

    FDA Approves Neratinib for Metastatic HER2-Positive Breast Cancer

    On February 25, 2020, the U.S. Food and Drug Administration (FDA) approved neratinib (Nerlyn®) in combination with capecitabine for adult patients with advanced or metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 based regimens in the metastatic setting.

    February 26, 2020
    Oncology Drug Reference Sheet: Niraparib
    Treatments

    Oncology Drug Reference Sheet: Niraparib

    Niraparib was approved in October 2019 for patients with homologous recombination deficiency (HRD)-positive advanced ovarian, fallopian tube, or primary peritoneal cancer. 

    February 25, 2020
    The Case of the CDK4/6 Inhibitors Checklist
    Immunotherapy

    The Case of the CDK4/6 Inhibitors Checklist

    Three years ago, Sarah, age 54, completed standard chemotherapy and radiation treatment for stage II, ER- and PR-positive, HER2-negative invasive breast cancer. A recent computed tomography scan, ordered to evaluate persistent hip pain, revealed bone lesions, and a biopsy and positron-emission tomography scan confirmed bone-only metastatic breast cancer. A CDK4/6 inhibitor, ribociclib, was added to the letrozole she was already taking.

    February 18, 2020
    Nurses Will Forge New Territory With Biosimilars in Cancer Care
    Treatments

    Nurses Will Forge New Territory With Biosimilars in Cancer Care

    Although cancer biosimilars have been used in European countries and in U.S. supportive care for some time, biologic medications are still new to cancer treatment in the United States. With greater support coming in at the federal level and from agencies like the U.S. Food and Drug Administration (FDA) and Federal Trade Commission, the rising biosimilar tide could soon reach a new highwater mark for healthcare professionals—and nurses specifically.

    February 13, 2020
    Immune-Related Adverse Events With PD-1 Inhibitors in Head and Neck Cancer
    Clinical practice

    Immune-Related Adverse Events With PD-1 Inhibitors in Head and Neck Cancer

    Clinical trial results show that PD-1 inhibitors offer improved survival and a better safety profile compared to standard, single-agent chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck. However, because of their mechanism of action as immunotherapy, patients receiving the agents may experience immune-related adverse events (irAEs).

    February 11, 2020
    Study Drug Plus Immunotherapy May Offer New Treatment Option for Lung and Kidney Cancer
    Treatments

    Study Drug Plus Immunotherapy May Offer New Treatment Option for Lung and Kidney Cancer

    Pegilodecakin, an investigational, first-in-class drug currently in clinical trials, is demonstrating positive safety results and measurable responses when used in combination with pembrolizumab or nivolumab in patients with non-small cell lung cancer (NSCLC) or kidney cancer. The findings from the multicenter, phase IB study were published in Lancet Oncology.

    January 28, 2020
    Prostate Cancer Prevention, Screening, Treatment, and Survivorship Recommendations
    Prostate cancer

    Prostate Cancer Prevention, Screening, Treatment, and Survivorship Recommendations

    One in nine men will be diagnosed with prostate cancer, the second leading cause of death in men in the United States. Survival varies greatly depending on the disease’s severity and extent at diagnosis: five-year survival rates are near 100% for local or regional disease, but they drop to 30% for metastatic prostate cancer.

    January 27, 2020
    FDA Approves Tazemetostat for Advanced Epithelioid Sarcoma
    U.S. Food and Drug Administration (FDA)

    FDA Approves Tazemetostat for Advanced Epithelioid Sarcoma

    On January 23, 2020, the U.S. Food and Drug Administration (FDA) granted accelerated approval to tazemetostat for adults and pediatric patients aged 16 years and older with metastatic or locally advanced epithelioid sarcoma not eligible for complete resection.

    January 24, 2020
    Trastuzumab Biosimilar Has Comparative Safety and Efficacy After Long-Term Follow-Up
    Treatments

    Trastuzumab Biosimilar Has Comparative Safety and Efficacy After Long-Term Follow-Up

    January 22, 2020
    Oncology Drug Reference Sheet: Entrectinib
    Treatments

    Oncology Drug Reference Sheet: Entrectinib

    Entrectinib was approved by the U.S. Food and Drug Administration in August 2019 as the third tumor-agnostic cancer drug, meaning it targets a specific mutation of the cancer, not the organ of origin. The other two currently approved tumor-agnostic drugs are larotrectinib and pembrolizumab.

    January 21, 2020
    FDA Approves Avapritinib for Gastrointestinal Stromal Tumor With a Rare Mutation
    U.S. Food and Drug Administration (FDA)

    FDA Approves Avapritinib for Gastrointestinal Stromal Tumors With a Rare Mutation

    On January 9, 2020, the U.S. Food and Drug Administration (FDA) approved avapritinib (AyvakitTM) for adults with unresectable or metastatic gastrointestinal stromal tumor harboring a platelet-derived growth factor receptor alpha exon 18 mutation, including D842V mutations.

    January 10, 2020
    FDA Approves Pembrolizumab for BCG-Unresponsive, High-Risk Non-Muscle Invasive Bladder Cancer
    U.S. Food and Drug Administration (FDA)

    FDA Approves Pembrolizumab for BCG-Unresponsive, High-Risk Non-Muscle Invasive Bladder Cancer

    On January 8, 2020, the U.S. Food and Drug Administration (FDA) approved pembrolizumab for the treatment of patients with Bacillus Calmette-Guerin unresponsive, high-risk, non-muscle invasive bladder cancer with carcinoma in situ with or without papillary tumors who are ineligible for or have elected not to undergo cystectomy.  

    January 08, 2020
    Oral Chemo Education Sheets Provide Key Education to Patients
    Patient Education

    Oral Chemo Education Sheets Provide Key Information to Patients

    Oral oncolytics have introduced a different level of complexity to care. Many patients won’t ever receive their treatments in the infusion room, which is where nurses have traditionally offered in-depth patient education. Instead, nurses are using new tools—like the Oral Chemo Education Sheets—to ensure patients have the information they need to understand their treatment and its side effects.

    January 01, 2020
    Oncology Drug Reference Sheet: Radium 223 Dichloride
    Treatments

    Oncology Drug Reference Sheet: Radium 223 Dichloride

    Radium 223 dichloride (Xofigo®) is an alpha particle-emitting radioactive therapeutic agent approved by the U.S. Food and Drug Administration in 2013 for castrate-resistant prostate cancer.

    December 24, 2019
    FDA approves fam-trastuzumab deruxtecan-nxki for unresectable or metastatic HER2-positive breast cancer
    U.S. Food and Drug Administration (FDA)

    FDA Approves Fam-Trastuzumab Deruxtecan-Nxki for Unresectable or Metastatic HER2-Positive Breast Cancer

    On December 20, 2019, the Food and Drug Administration granted accelerated approval to fam-trastuzumab deruxtecan-nxki (Enhertu®) for patients with unresectable or metastatic HER2-positive breast cancer who have received two or more prior anti-HER2-based regimens in the metastatic setting.

    December 20, 2019
    FDA Grants Accelerated Approval to Enfortumab Vedotin-ejfv for Metastatic Urothelial Cancer
    U.S. Food and Drug Administration (FDA)

    FDA Grants Accelerated Approval to Enfortumab Vedotin-ejfv for Metastatic Urothelial Cancer

    On December 18, 2019, the U.S. Food and Drug Administration granted accelerated approval to enfortumab vedotin-ejfv (PadcevTM) for adult patients with locally advanced or metastatic urothelial cancer who have previously received a programmed death receptor-1 (PD-1) or programmed death-ligand 1 inhibitor, and a platinum-containing chemotherapy in the neoadjuvant/adjuvant, locally advanced or metastatic setting.

    December 19, 2019
    Combining Tamoxifen and Blue Light Can Better Target CAR T Cells
    Research

    Combining Tamoxifen and Blue Light Can Better Target CAR T Cells

    Bioengineers may have found a way to use tamoxifen activated with blue light to control precisely which tissues and body areas CAR T cells attack, reducing toxicities in other parts of the body. They reported their work in ACS Synthetic Biology.

    December 18, 2019
    FDA Approves Enzalutamide for Metastatic Castration-Sensitive Prostate Cancer
    U.S. Food and Drug Administration (FDA)

    FDA Approves Enzalutamide for Metastatic Castration-Sensitive Prostate Cancer

    On December 16, 2019, the U.S. Food and Drug Administration (FDA) approved enzalutamide (Xtandi®) for patients with metastatic castration-sensitive prostate cancer.

    December 17, 2019
    Newer Therapies at Last Offer Systemic Options for Metastatic HCC
    Advanced Practice Nursing (APRN)

    Newer Therapies at Last Offer Systemic Options for Metastatic HCC

    Already the third leading cause of cancer deaths worldwide, hepatocellular carcinoma (HCC) is a continually growing burden as the incidence of obesity, type II diabetes, and hypertension also increase, which may lead to cirrhosis and nonalcoholic fatty liver disease. Its incidence is highest in Asia and Africa, where the prevalence of hepatitis B and hepatitis C may result in chronic liver disease and subsequently HCC. 

    December 12, 2019
    FDA Approves Atezolizumab With Paclitaxel Protein-Bound and Carboplatin for Metastatic NSCLC Without EGFR/ALK Aberrations
    U.S. Food and Drug Administration (FDA)

    FDA Approves Atezolizumab With Paclitaxel Protein-Bound and Carboplatin for Metastatic NSCLC Without EGFR/ALK Aberrations

    On December 3, 2019, the U.S. Food and Drug Administration (FDA) approved atezolizumab (Tecentriq®) in combination with paclitaxel protein-bound and carboplatin for the first-line treatment of adult patients with metastatic non-squamous non-small cell lung cancer (NSCLC) with no EGFR or ALK genomic tumor aberrations.

    December 05, 2019
    CDK4/6 Plus AI Is Effective for Older Women With Breast Cancer
    Breast cancer

    CDK4/6 Plus AI Is Effective for Older Women With Breast Cancer

    Combination treatment with a CDK4/6 inhibitor and aromatase inhibitor (AI) results in similar progression-free survival (PFS) rates in women with hormone receptor-positive, HER2-negative metastatic breast cancer who are aged 70 or older compared to younger women, according to study findings published in the Journal of Clinical Oncology.

    December 04, 2019
    B. Braun Recalls Certain Lots of Blood Administration Sets
    Safety

    B. Braun Recalls Certain Lots of Blood Administration Sets

    Because of the potential for leakage at the joint between the blood filters and tubing, B. Braun issued a voluntary recall of 22 lots of its y-type blood administration sets in November 2019. The recalled sets are used to deliver blood from a container to a patient's vascular system through an IV catheter inserted into a vein or central venous catheter.

    December 03, 2019
    Oncology Drug Reference Sheet: Blinatumomab (Blincyto®)
    Treatments

    Oncology Drug Reference Sheet: Blinatumomab

    Blinatumomab received accelerated approval from the U.S. Food and Drug Administration (FDA) in 2014 for the treatment of B-cell precursor acute lymphoblastic leukemia. The drug’s unique administration procedures have prompted nurses to evaluate their practice for safety.

    November 27, 2019
    FDA Approves Acalabrutinib for CLL and SLL
    U.S. Food and Drug Administration (FDA)

    FDA Approves Acalabrutinib for CLL and SLL

    On November 21, 2019, the U.S. Food and Drug Administration (FDA) approved acalabrutinib (Calquence®) for adults with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).

    November 21, 2019
    Do Antibiotics Affect Response to Immune Checkpoint Inhibitors?
    Research

    Do Antibiotics Affect Response to Immune Checkpoint Inhibitors?

    Receiving antibiotics in the 30 days prior to starting immune checkpoint inhibitor treatment was associated with significantly reduced median overall survival, according to findings from a study published in JAMA Oncology. However, antibiotic use during treatment had no effect on survival.

    November 20, 2019
    The Case of the Efficacy Explanation
    Treatments

    The Case of the Efficacy Explanation

    Jenni is an oncology nurse practitioner in an outpatient medical oncology clinic. She is meeting with 70-year-old Don after his first cycle of cabozantinib for treatment of metastatic medullary thyroid carcinoma when he asks why the oncologist put him on a pill instead of using IV chemotherapy. “Is it because I don’t have long to live?” Don wonders.

    November 19, 2019
    FDA Grants Accelerated Approval to Zanubrutinib for Mantle Cell Lymphoma
    U.S. Food and Drug Administration (FDA)

    FDA Grants Accelerated Approval to Zanubrutinib for Mantle Cell Lymphoma

    On November 14, 2019, the U.S. Food and Drug Administration (FDA) granted accelerated approval to zanubrutinib (Brukinsa™) for adult patients with mantle cell lymphoma who have received at least one prior therapy.

    November 15, 2019
    FDA Approves Niraparib for HRD-Positive Advanced Ovarian Cancer
    U.S. Food and Drug Administration (FDA)

    FDA Approves Niraparib for HRD-Positive Advanced Ovarian Cancer

    On October 23, 2019, the U.S. Food and Drug Administration (FDA) approved niraparib (Zejula®) for patients with advanced ovarian, fallopian tube, or primary peritoneal cancer treated with three or more prior chemotherapy regimens and whose cancer is associated with homologous recombination deficiency (HRD)-positive status. HRD is defined by either a deleterious or suspected deleterious BRCA mutation, or genomic instability in patients with disease progression greater than six months after response to the last platinum-based chemotherapy.

    October 24, 2019
    Small Study Shows T-Cell Activity in Pancreatic Cancer
    Research

    Small Study Shows T-Cell Activity in Pancreatic Cancer

    When treated with their own nonengineered T cells plus chemotherapy, six of seven patients with inoperable or metastatic pancreatic cancer showed objective responses or stable disease, according to the results of a study reported at the American Association for Cancer Research’s Immune Cell Therapies for Cancer conference in July 2019.

    October 23, 2019
    Plan Ahead to Ensure Consistency in Patient Care and Communication During Drug Shortages
    U.S. Food and Drug Administration (FDA)

    Plan Ahead to Ensure Consistency in Patient Care and Communication During Drug Shortages

    A manufacturing delay leading to a shipping delay caused the October 2019 vincristine shortage, according to a letter Pfizer sent to its customers on October 18; the U.S. Food and Drug Administration first reported the shortage on October 16. It affects both the 1 mg/ml and 2 mg/2 ml single-dose ONCO-TAIN™ glass fliptop vials.

    October 22, 2019
    • Current page 1
    • Page 2
    • Page 3
    • Page 4
    • Page 5
    • Page 6
    • Next page
    • Last page Last »
    Trending Topics
    • Research
    • Treatments
    • Safety
    • COVID-19
    • Drug Reference Sheet
    • Special Populations
    • Clinical practice
    • U.S. Food and Drug Administration (FDA)
    • Health Policy
    • Immunotherapy
    View All Topics
     
    Home
    News, Views, and Advocacy From the Oncology Nursing Society
  • Legal Notices
  • Contact Us
  • Conferences
  • Advertising
  • Newsroom
  • Sitemap
  • Instagram
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • RSS
  • ONS
  • Oncology Nursing Foundation
  • ONCC
  • © Copyright 2023 Oncology Nursing Society
     
    Back to Top ▲